{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:14:04Z","timestamp":1782321244573,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007512","name":"Universitat Rovira i Virgili","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.numecd.2025.104199","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:01:47Z","timestamp":1750276907000},"page":"104199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Widespread lipoprotein alterations in a REDUCE-IT like population: The icosapent ethyl (IPE)-NMR avatar study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-4954","authenticated-orcid":false,"given":"Llu\u00eds","family":"Masana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Torn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Garcia-Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Dalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Amig\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.numecd.2025.104199_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"issue":"9943","key":"10.1016\/j.numecd.2025.104199_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and 2disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.numecd.2025.104199_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jacc.2018.12.075","article-title":"Vascular inflammation in subclinical atherosclerosis detected by hybrid PET\/MRI","volume":"73","author":"Fern\u00e1ndez-Friera","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.numecd.2025.104199_bib4","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.numecd.2025.104199_bib5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104199_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2025.104199_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.numecd.2025.104199_bib8","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.numecd.2025.104199_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104199_bib10","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: a consensus statement","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2025.104199_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.numecd.2025.104199_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14132","article-title":"Lipidomics of triglyceride-rich lipoproteins on inflammation","volume":"54","author":"Moreno-Vedia","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2025.104199_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020354","article-title":"Human serum\/plasma glycoprotein analysis by 1H-NMR","volume":"9","author":"Fuertes-Mart\u00edn","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2025.104199_bib14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/clc.23069","article-title":"Associations of ideal cardiovascular health with GlycA","volume":"41","author":"Benson","year":"2018","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104199_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.numecd.2025.104199_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurheartj\/ehad889","article-title":"Icosapent ethyl following acute coronary syndrome","volume":"45","author":"Sayah","year":"2024","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.numecd.2025.104199_bib17","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2017-0067","article-title":"Omega-3 fatty acids in atherosclerosis","volume":"3","author":"B\u00e4ck","year":"2017","journal-title":"Future Sci OA"},{"issue":"18","key":"10.1016\/j.numecd.2025.104199_bib18","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1093\/cvr\/cvad188","article-title":"Do patients benefit from omega-3 fatty acids?","volume":"119","author":"Sherratt","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.numecd.2025.104199_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1194\/jlr.D050120","article-title":"Liposcale: a novel advanced lipoprotein test","volume":"56","author":"Mallol","year":"2015","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.numecd.2025.104199_bib20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.numecd.2025.104199_bib21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/ehjcvp\/pvae030","article-title":"Effects of icosapent ethyl in atherosclerotic cardiovascular disease","volume":"10","author":"Burger","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"10.1016\/j.numecd.2025.104199_bib22","first-page":"192","article-title":"The athero-contour","volume":"34","author":"Lin","year":"2024","journal-title":"Cl\u00edn Invest Arterioscler"},{"issue":"2","key":"10.1016\/j.numecd.2025.104199_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14101","article-title":"Association between air pollution and blood lipids","volume":"54","author":"Vald\u00e9s","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2025.104199_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.recesp.2021.02.013","article-title":"Advanced lipoprotein profile in glucose metabolism","volume":"75","author":"Puig-Jov\u00e9","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.numecd.2025.104199_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2362.2003.01263.x","article-title":"Alterations in HDL metabolism in diabetes","volume":"33","author":"Borggreve","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2025.104199_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvae222","article-title":"Small remnants vs. large triglyceride-lipoproteins","author":"Wadstrom","year":"2025","journal-title":"Clin Chem"},{"issue":"Supplement_2","key":"10.1016\/j.numecd.2025.104199_bib27","doi-asserted-by":"crossref","first-page":"ehad655","DOI":"10.1093\/eurheartj\/ehad655.1309","article-title":"Eicosapentaenoic acid and triglyceride levels in REDUCE-IT","volume":"44","author":"Szarek","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.numecd.2025.104199_bib28","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for hypertriglyceridemia","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.numecd.2025.104199_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacl.2012.07.001","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)","volume":"6","author":"Bays","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.numecd.2025.104199_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jacl.2014.11.009","article-title":"Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)","volume":"9","author":"Ballantyne","year":"2015","journal-title":"J Clin Lipidol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325003539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325003539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:37:33Z","timestamp":1762331853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325003539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0939475325003539"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104199","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Widespread lipoprotein alterations in a REDUCE-IT like population: The icosapent ethyl (IPE)-NMR avatar study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104199"}}